Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 18/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5743979 | 0.92 | MAOA (0.61) | MAOACYP3A4CYP2D6MAOBKCNH2 | |
| SCHEMBL5744532 | 0.90 | MAOA (0.76) | MAOACYP3A4CYP2D6 | |
| SCHEMBL5232210 | 0.86 | MAOA (0.80) | MAOACYP3A4CYP2D6MAOBKCNH2 | |
| SCHEMBL5743011 | 0.85 | MAOA (0.68) | MAOACYP3A4CYP2D6MAOBKCNH2 | |
| SCHEMBL5742132 | 0.85 | MAOA (0.68) | MAOACYP3A4CYP2D6MAOBKCNH2 | |
| SCHEMBL5742127 | 0.85 | MAOA (0.68) | MAOACYP3A4CYP2D6MAOBKCNH2 | |
| SCHEMBL5233903 | 0.77 | MAOA (0.56) | MAOACYP3A4CYP2D6MAOBKCNH2 | |
| SCHEMBL5229080 | 0.77 | MAOA (0.56) | MAOACYP3A4CYP2D6MAOBKCNH2 | |
| SCHEMBL5742018 | 0.77 | MAOA (0.56) | MAOACYP3A4CYP2D6MAOBKCNH2 | |
| SCHEMBL5743308 | 0.77 | MAOA (0.51) | MAOACYP3A4CYP2D6MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1385844-B1 | OXAZOLIDINONES CONTAINING A SULFONIMID GROUP AS ANTIBIOTICS | ASTRAZENECA AB (SE) | 2006-07-05 | — | — | EP | disclosed |
| US-20050032861-A1 | Oxazolidines containing a sulfonimid group as antibiotics | ASTRAZENECA AB (SE) | 2005-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032861-A1 | Oxazolidines containing a sulfonimid group as antibiotics | SULT1E1, STS, OXA1L | MAOA 963/4885CYP3A4 46/4885CYP2D6 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.